Current reports
6-K
Relief Therapeutics Announces New Executive Leadership Team strengthening capabilities to guide the Company through pipeline development initiatives
10 May 24
6-K
Invitation to the Extraordinary Shareholders' Meeting of RELIEF THERAPEUTICS Holding SA
3 Apr 24
6-K
Form 6-K Report of Foreign Private Issuer for March, 2024
27 Mar 24
6-K
Form 6-K Report of Foreign Private Issuer for February, 2024
28 Feb 24
6-K
Relief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D Growth
5 Dec 23
6-K
Relief Therapeutics Announces CEO Transition
22 Nov 23
6-K
Form 6-K Report of Foreign Private Issuer for October, 2023
10 Oct 23
6-K
Current report (foreign)
15 Sep 23
6-K
Relief Therapeutics Announces New Exclusive Definitive License Agreement for OLPRUVAâ„¢ (ACER-001) with Acer Therapeutics
31 Aug 23
6-K
RELIEF THERAPEUTICS Holding SA Announces CHF 5 Million Private Placement
23 Jun 23
Registration and prospectus
F-6 POS
Automatic registration for ADRs (post-effective amendment, foreign)
24 Apr 23
RW
Registration withdrawal request
7 Feb 23
F-1/A
Registration statement (foreign) (amended)
23 Dec 22
F-1/A
Registration statement (foreign) (amended)
15 Nov 22
F-6 POS
Automatic registration for ADRs (post-effective amendment, foreign)
21 Oct 22
F-1
Registration statement (foreign)
23 Aug 22
F-6 POS
Automatic registration for ADRs (post-effective amendment, foreign)
1 Aug 22
20FR12G
Initial registration of securities (foreign private issuers)
11 Jul 22
RW
Registration withdrawal request
11 Jul 22
20FR12B/A
Initial registration of securities (foreign private issuers) (amended)
1 Jul 22
Proxies
No filings